中国实用眼科杂志
中國實用眼科雜誌
중국실용안과잡지
CHINESE JOURNAL OF PRACTICAL OPHTHALMOLOGY
2014年
1期
37-40
,共4页
青光眼%治疗%睫状体光凝%二极管激光
青光眼%治療%睫狀體光凝%二極管激光
청광안%치료%첩상체광응%이겁관격광
Glaucoma%Treatment%Diode laser%Cyclophotocoagulation
目的 观察二极管激光经巩膜睫状体光凝(transcleral cyclophotocoagulation)治疗难治性青光眼的疗效及安全性.方法 临床病例对照研究.自2009年1月至2012年12月间,在天津市眼科医院共收治各类难治性青光眼患者162例(162只眼),其中男76例,女86例;平均年龄(54.7±12.3)岁(22~81岁).按青光眼诊断类型分为三组:滤过性手术后开角型青光眼组51例,闭角型青光眼组50例,新生血管青光眼组61例,所有患者对既往药物及手术治疗效果均不理想,眼压持续升高.所有患者接受二极管激光经巩膜睫状体光凝治疗,随访观察三组患者治疗前后眼压、前房深度和视力改变.结果 三组患者经治疗后眼压明显下降,差异有统计学意义(F =3.84,P=0.024,P<0.05),治疗后各组患者之间眼压差异无统计学意义(F =0.99~1.84,P>0.05).末次随访时平均眼压较治疗前下降54.2%,其中达到临床治愈标准者124例,手术有效率为76.5%.治疗后三组患者平均前房深度均有加深,差异有统计学意义(t =6.21,P=0.000,P<0.05).其中以闭角型青光眼改变明显(t=7.64,P =0.000,P<0.05),开角型青光眼和新生血管青光眼患者差异无统计学意义(t=1.85,1.86,P=0.07,P>0.05).治疗后最佳矫正视力有轻度改善者27例(16.7%),视力稳定者112例(69.1%),视力下降者23例(14.2%).患者对手术耐受良好,少数患者出现轻度前葡萄膜炎、前房出血或角膜水肿,但无低眼压、眼球萎缩及交感性眼炎发生.结论 二极管激光经巩膜睫状体光凝术对难治性青光眼具有良好地降眼压效果,且操作简单、安全有效和患者痛苦小,可作为难治性青光眼的有效治疗手段.
目的 觀察二極管激光經鞏膜睫狀體光凝(transcleral cyclophotocoagulation)治療難治性青光眼的療效及安全性.方法 臨床病例對照研究.自2009年1月至2012年12月間,在天津市眼科醫院共收治各類難治性青光眼患者162例(162隻眼),其中男76例,女86例;平均年齡(54.7±12.3)歲(22~81歲).按青光眼診斷類型分為三組:濾過性手術後開角型青光眼組51例,閉角型青光眼組50例,新生血管青光眼組61例,所有患者對既往藥物及手術治療效果均不理想,眼壓持續升高.所有患者接受二極管激光經鞏膜睫狀體光凝治療,隨訪觀察三組患者治療前後眼壓、前房深度和視力改變.結果 三組患者經治療後眼壓明顯下降,差異有統計學意義(F =3.84,P=0.024,P<0.05),治療後各組患者之間眼壓差異無統計學意義(F =0.99~1.84,P>0.05).末次隨訪時平均眼壓較治療前下降54.2%,其中達到臨床治愈標準者124例,手術有效率為76.5%.治療後三組患者平均前房深度均有加深,差異有統計學意義(t =6.21,P=0.000,P<0.05).其中以閉角型青光眼改變明顯(t=7.64,P =0.000,P<0.05),開角型青光眼和新生血管青光眼患者差異無統計學意義(t=1.85,1.86,P=0.07,P>0.05).治療後最佳矯正視力有輕度改善者27例(16.7%),視力穩定者112例(69.1%),視力下降者23例(14.2%).患者對手術耐受良好,少數患者齣現輕度前葡萄膜炎、前房齣血或角膜水腫,但無低眼壓、眼毬萎縮及交感性眼炎髮生.結論 二極管激光經鞏膜睫狀體光凝術對難治性青光眼具有良好地降眼壓效果,且操作簡單、安全有效和患者痛苦小,可作為難治性青光眼的有效治療手段.
목적 관찰이겁관격광경공막첩상체광응(transcleral cyclophotocoagulation)치료난치성청광안적료효급안전성.방법 림상병례대조연구.자2009년1월지2012년12월간,재천진시안과의원공수치각류난치성청광안환자162례(162지안),기중남76례,녀86례;평균년령(54.7±12.3)세(22~81세).안청광안진단류형분위삼조:려과성수술후개각형청광안조51례,폐각형청광안조50례,신생혈관청광안조61례,소유환자대기왕약물급수술치료효과균불이상,안압지속승고.소유환자접수이겁관격광경공막첩상체광응치료,수방관찰삼조환자치료전후안압、전방심도화시력개변.결과 삼조환자경치료후안압명현하강,차이유통계학의의(F =3.84,P=0.024,P<0.05),치료후각조환자지간안압차이무통계학의의(F =0.99~1.84,P>0.05).말차수방시평균안압교치료전하강54.2%,기중체도림상치유표준자124례,수술유효솔위76.5%.치료후삼조환자평균전방심도균유가심,차이유통계학의의(t =6.21,P=0.000,P<0.05).기중이폐각형청광안개변명현(t=7.64,P =0.000,P<0.05),개각형청광안화신생혈관청광안환자차이무통계학의의(t=1.85,1.86,P=0.07,P>0.05).치료후최가교정시력유경도개선자27례(16.7%),시력은정자112례(69.1%),시력하강자23례(14.2%).환자대수술내수량호,소수환자출현경도전포도막염、전방출혈혹각막수종,단무저안압、안구위축급교감성안염발생.결론 이겁관격광경공막첩상체광응술대난치성청광안구유량호지강안압효과,차조작간단、안전유효화환자통고소,가작위난치성청광안적유효치료수단.
Objective To evaluate the efficacy and safety of diode laser transscleral cyclophotocoagulation (TSCP) in the treatment of refractory glaucoma.Methods From January 2009 to December 2012,a total of 162 eyes (162 patients) with advanced glaucoma refractory to medical treatment in Tianjin Eye Hospital were collected.The male patients were 76 cases and the females were 86cases.The average age was (54.7±12.3) years old (range 22-81 years).There were 51 cases with primary open angle glaucoma (POAG),50 cases with primary angle-closure glaucoma (PACG) and 61cases of patients with neovascular glaucoma (NVG).All the affected eyes had higher intraocular pressure (IOP) even through the maximal medication.All the patients were undergone the TSCP treatment.The IOP,anterior chamber depth,corrected visual acuity and complications were observed and follow-up.Results The mean postoperative IOP was decreased and the difference was significant before and after the treatment (F=3.84,P =0.024),the postoperative IOP at the different groups were not significant difference (F=0.99-1.84,P >0.05).The IOP decreased rate was 54.2% between the first and the last visit.The success rate was 76.5% after twelve months follow-up.The anterior chamber depth of all patients was deeper after the treatment and the difference was significant (t =6.21,P =0.000).The anterior chamber depth of the patients with PACG was changed significantly (t =7.64,P =0.000) and there was no significant difference (t =1.85/1.86,P =0.07) among the patients with POAG and NVG.Compared to the initial visit,the corrected visual acuity at last visit was increased in 27 cases (16.7%) of the patients,112 cases (69.1%) was stable and 23 cases (14.2%) was decreased.Most of the patients were tolerant with the treatment,and some patients had slight anterior uveitis,hyphema or corneal edema.There was not hypotension,sympathetic ophthalmia or phthisis bulbi.Conclusions TSCP can decrease the intraocular pressure evidently and relieve pain from the patients with refractory glaucoma.It is an effective,simple and safe method for the treatment of refractory glaucoma.